Skip to main content
. 2018 Oct 17;7(10):364. doi: 10.3390/jcm7100364

Table 3.

Adjusted Cox Proportional Hazard Model for overall survival.

Variable Hazard Ratio 95% CI p Value
Age 1.04 1.00–1.07 0.029
Woman 0.48 0.26–0.89 0.019
Patient-reported education
No diploma (reference)
High school 0.42 0.22–0.81 0.009
Bachelor degree 0.41 0.16–1.06 0.07
>Bachelor 0.50 0.14–1.70 0.26
Patient-reported financial situation
Not at all or not very comfortable (reference)
Moderately comfortable 1.42 0.58–3.45 0.44
Rather or very comfortable 1.27 0.46–3.57 0.65
Type and severity of cancer
Stage I, II or III (NSCL or SCL) (reference category)
Stage IV (NSCL or SCL) 3.14 1.22–8.09 0.018
Mesothelioma (no stage assigned) 3.30 1.22–8.91 0.018
Karnofsky index 60–70 (compared to >70) 2.53 0.84–7.59 0.10
Time since diagnosis and inclusion in the study 0.98 0.84–1.14 0.75
Charlson index of comorbidities 1.02 0.88–1.17 0.80
Mutation (ALK, EGFR, ROS vs. none of them) 1.40 0.64–3.06 0.40
Metastases 0.92 0.38–2.25 0.85
Cancer-related emotional distress 1.06 1.01–1.12 0.03
Emotional skills 1.57 0.87–2.85 0.14
Patient-reported physician empathy - - -
Type of consultation (bad news vs. follow-up) - - -
Empathy * type-of-consultation (interaction) 0.022
Empathy in bad news consultations 1.06 1.01–1.12 0.024
Empathy in follow-up consultations 0.96 0.90–1.03 0.24

NSCL: Non-small cell lung cancer; SCL: Small cell lung cancer; n = 143 (due to missing data in some variables), -2LL = 587.8, Akaike Information Criterion (AIC) = 625.8, Schwarz Bayesian Criterion (SBC) = 668.8. EGFR: Epidermal Growth Factor Receptor; ALK: Anaplastic Lymphoma Kinase; ROS: ROS proto-oncogene 1, receptor tyrosine kinase.